|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ƥ��,������ |
|
ҩ�ﶾ�� |
| ��������������� | |
|
�¼� |
|
��ѧ˼ |
| PubMed | |
|
Article by CHEN Jia |
|
Article by ZENG Xue-si |
ҩ���Ժ�Ƥ��
�¼�, ��ѧ˼
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
����ҩ���ʹ�ú���ҩ�Ŀ���Ӧ��,ҩ���������ĺ�Ƥ������������,����ҩҲ�����ࡣ���������ɴ���ȿ�����ҩ�ﳬ����Ӧ�ۺ��������������ù�صȷֱ�����𰱱���ۺ����������ۺ�������Ƥ����Ϊ��Щ�ۺ�����Ƥ������,Ҳ�ɵ������֡�ҩ���Ժ�Ƥ��Ӧ������ԭ�����º�Ƥ�������
Drug-Induced Erythroderma
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Along with the development and application of new drugs, the incidence of drug-induced erythro-derma tends to increase, so does the number of sensitizing drugs. Spironolactone and codeine can cause drug hypersensitivity syndrome, while dapsone and vancomycin can cause dapsone syndrome and red-man syndrome respectively. Erythroderma can be the skin manifestation of these syndromes, or occurs alone. It is important to differentiate erythroderma induced by drugs from that by other causes.
[2] Sullivan JR,Shear NH.The drug hypersensitivity syndrome:what is the pathogenesis? Arch Dermatol,2001,137:357-364.
[3] Ghislain PD,Bodarwe AD,Vanderdonckt O,et al.Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone:DRESS syndrome.Acta Derm Venereol,2004,84:65-68.
[4] Enomoto M,Ochi M,Teramae K,et al.Codeine phosphate-induced hypersensitivity syndrome.Ann Pharmacother,2004,38:799-802.
[5] Lawrenson RA,Seaman HE,Sundstrom A,et al.Liver damage associated with minocycline use in acne:a systematic review of the published literature and pharmacovigilance data.Drug Saf,2000,23:333-349.
[6] Lee KB,Nashed TB.Dapsone-induced sulfone syndrome.Ann Pharmacother,2003,37:1044-1046.
[7] Prasad PV.A study of dapsone syndrome at a rural teaching hospital in South India.Indian J Dermatol Venereol Leprol,2001,67:69-71.
[8] Itha S,Kumar A,Dhingra S,et al.Dapsone induced cholangitis as a part of dapsone syndrome:a case report.BMC Gastroenterol,2003,3:21.
[9] Bucaretchi F,Vicente DC,Pereira RM,et al.Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.Rev Inst Med Trop Sao Paulo,2004,46:331-334.
[10] Sivagnanam S,Deleu D.Red man syndrome.Crit Care,2003,7:119-120.
[11] Wilson AP.Comparative safety of teicoplanin and vancomycin.Int J Antimicrob Agents,1998,10:143-152.
[12] Renz CL,Thurn JD,Finn HA,et al.Antihistamine prophylaxis permits rapid vancomycin infusion.Crit Care Med,1999,27:1732.
[13] Hall VC,El-Azhary RA,Bouwhuis S,et al.Dermatologic side effects of thalidomide in patients with multiple myeloma.J Am Acad Dermatol,2003,48:548-552.
[14] Asnis LA,Gaspari AA.Cutaneous reactions to recombinant cytokine therapy.J Am Acad Dermatol,1995,33:393-410.
[15] Gallelli L,Ferraro M,Mauro GF,et al.Generalized exfoliative dermatitis induced by interferon alfa.Ann Pharmacother,2004,38:2173-2174.
[16] Wolf IH,Smolle J,Cerroni L,et al.Erythroderma with lichenoid granulomatous features induced by erythropoietin.J Cutan Pathol,2005,32:371-374.
[17] Ghura HS,Carmichael AJ,Bairstow D,et al.Fatal erythroderma associated with pentostatin.BMJ,1999,319:549.
[18] Banka N,Aljurf M,Hamadah I.Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.Dermatology,2003,207:329-330.
[19] Cox NH,Gordon PM,Dodd H.Generalized pustular and erythrodermic psoriasis associated with bupropion treatment.Br J Dermatol,2002,146:1061-1063.
[20] Sarkar R,Sharma RC,Koranne RV,et al.Erythroderma in children:a clinico-etiological study.J Dermatol,1999,26:507-511.
[21] Pruszkowski A,Bodemer C,Fraitag S,et al.Neonatal and infantile erythrodermas:a retrospective study of 51 patients.Arch Dermatol,2000,136:875-880.